Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4059432 | 1.00 | CPT1A (0.52) | CPT1ACPT2 | |
| SCHEMBL2890744 | 0.97 | CPT1A (0.48) | CPT1ACPT2 | |
| SCHEMBL2890738 | 0.97 | CPT1A (0.48) | CPT1ACPT2 | |
| SCHEMBL5303450 | 0.89 | CPT1A (0.52) | CPT1ACPT2 | |
| SCHEMBL5303447 | 0.89 | CPT1A (0.52) | CPT1ACPT2 | |
| SCHEMBL5314047 | 0.89 | CPT1A (0.52) | CPT1ACPT2 | |
| SCHEMBL2894183 | 0.86 | POLB (0.49) | CPT1ACPT2 | |
| SCHEMBL2894182 | 0.86 | POLB (0.49) | CPT1ACPT2 | |
| SCHEMBL3966278 | 0.86 | CPT1A (0.52) | CPT1ACPT2 | |
| SCHEMBL3962625 | 0.86 | CPT1A (0.52) | CPT1ACPT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2027090-A2 | MGLUR5 MODULATORS II | AstraZeneca AB (SE) | 2009-02-25 | — | — | EP | claimed |
| WO-2007130821-A2 | MGLUR5 MODULATORS II | ASTRAZENECA AB (SE) | 2007-11-15 | — | — | WO | claimed |
| US-20070259916-A1 | mGluR5 modulators II | ASTRAZENECA AB (SE) | 2007-11-08 | — | — | US | claimed |
| WO-2007130821-A2 | MGLUR5 MODULATORS II | ASTRAZENECA AB (SE) | 2007-11-15 | — | — | WO | disclosed |
| US-20070259916-A1 | mGluR5 modulators II | ASTRAZENECA AB (SE) | 2007-11-08 | — | — | US | disclosed |
| US-20070259916-A1 | mGluR5 modulators II | ASTRAZENECA AB (SE) | 2007-11-08 | — | — | US | disclosed |
| US-20070259916-A1 | mGluR5 modulators II | ASTRAZENECA AB (SE) | 2007-11-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070259916-A1 | mGluR5 modulators II | GRM5, GRM2, GRIK5 | CPT1A 1642/4885CPT2 750/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.